|Day's Range||19.20 - 20.60|
(Reuters) -U.S. scientific instruments maker Thermo Fisher Scientific Inc and South Korea's Celltrion Inc are among those competing to acquire the biopharma solutions business of medical device maker Baxter International Inc, according to people familiar with the matter. The divestment, which the sources said could fetch more than $4 billion, would help Baxter pay down debt following its $10.5 billion acquisition of medical device maker Hill-Rom Holdings in 2021. Private equity firms, including KKR & Co and Carlyle Group, have also expressed interest in the Baxter business, the sources said.
In the latest trading session, Thermo Fisher Scientific (TMO) closed at $547.34, marking a -1.75% move from the previous day.
When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...